These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38071314)

  • 21. Th1 immune response to Plasmodium falciparum recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice.
    Mehrizi AA; Ameri Torzani M; Zakeri S; Jafary Zadeh A; Babaeekhou L
    Parasite Immunol; 2018 Jul; 40(7):e12538. PubMed ID: 29799636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
    Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
    Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The malaria blood stage antigen PfCyRPA formulated with the TLR-4 agonist adjuvant GLA-SE elicits parasite growth inhibitory antibodies in experimental animals.
    Tamborrini M; Schäfer A; Hauser J; Zou L; Paris DH; Pluschke G
    Malar J; 2023 Jul; 22(1):210. PubMed ID: 37454145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
    Younis S; Faber BW; Kocken CHM; Remarque EJ
    BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.
    Shabani SH; Zakeri S; Mortazavi Y; Mehrizi AA
    Med Microbiol Immunol; 2019 Dec; 208(6):731-745. PubMed ID: 31025102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimized Refolding Buffers Oriented Humoral Immune Responses Versus PfGCS1 Self-Assembled Peptide Nanoparticle.
    Nourani L; Lotfi A; Vand-Rajabpour H; Pourhashem Z; Nemati F; Mehrizi AA
    Mol Biotechnol; 2024 Jan; ():. PubMed ID: 38267696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
    Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
    Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.
    Qiu Y; Zhao Y; Liu F; Ye B; Zhao Z; Thongpoon S; Roobsoong W; Sattabongkot J; Cui L; Fan Q; Cao Y
    Vaccine; 2020 Mar; 38(13):2841-2848. PubMed ID: 32093983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine.
    Yu X; Min H; Yao S; Yao G; Zhang D; Zhang B; Chen M; Liu F; Cui L; Zheng L; Cao Y
    Int Immunopharmacol; 2024 Apr; 131():111817. PubMed ID: 38460299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of the heterologous expression and purification of Plasmodium falciparum generative cell specific 1 in Escherichia coli.
    Ayoub Meigouni M; Abouie Mehrizi A; Fazaeli A; Zakeri S; Djadid ND
    Protein Expr Purif; 2022 Oct; 198():106126. PubMed ID: 35661702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.
    Gozar MM; Muratova O; Keister DB; Kensil CR; Price VL; Kaslow DC
    Exp Parasitol; 2001 Feb; 97(2):61-9. PubMed ID: 11281702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterologous Expression and Evaluation of Novel
    de Jong RM; Singh SK; Teelen K; van de Vegte-Bolmer M; van Gemert GJ; Stone WJR; Locke E; Plieskatt J; Theisen M; Bousema T; Jore MM
    Front Immunol; 2022; 13():909060. PubMed ID: 35812379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and development of a self-assembling protein nanoparticle displaying PfHAP2 antigenic determinants recognized by natural acquired antibodies.
    Zahedi F; Abouie Mehrizi A; Sardari S; Alemzadeh I
    PLoS One; 2022; 17(9):e0274275. PubMed ID: 36094917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles.
    Kumar R; Ledet G; Graves R; Datta D; Robinson S; Bansal GP; Mandal T; Kumar N
    Pharm Res; 2015 Dec; 32(12):3827-36. PubMed ID: 26113235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strong concordance between percent inhibition in oocyst and sporozoite intensities in a Plasmodium falciparum standard membrane-feeding assay.
    Miura K; Swihart BJ; Deng B; Zhou L; Pham TP; Diouf A; Fay MP; Long CA
    Parasit Vectors; 2019 May; 12(1):206. PubMed ID: 31060594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.